Dropping two drug candidates puts Genmab in a better position, says CEO
Genmab made a rare move during Q3 by scrapping two candidates. However, neither CEO Jan van de Winkel nor a Sydbank analyst think the decision will have much of an impact on the company's future.
BY ANDREAS LØNSTRUP, TRANSLATED BY CATHERINE BRETT
It isn't every day that biotech company Genmab has to abandon a drug under development.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
